Study Summary
The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.
Interested in this trial?
Submit an InquiryInterventions
CD19-targeted CAR-T cellsBIOLOGICAL
MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Qingdao Central Hospital | Qingdao | Shandong | China |